LFSC Fees and Costs — F/m Emerald Life Sciences Innovation ETF
Data updated: 2026-07-28
The net expense ratio is 0.54% (0.79% before fee waivers). There are no sales loads or redemption fees. Portfolio turnover was 19%.
LFSC Fees and Expenses
Annual operating expenses and sales charges of LFSC. Prospectus, as of December 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.79% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.79% |
| Fee waiver | −0.25% |
| Net expense ratio | 0.54% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
LFSC Costs Over Time
On $10,000 invested in LFSC, assuming 5% a year before costs, total costs come to $341 over 5 years, cutting the return by 0.57% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.54%) | $57 | $178 | $310 |
| Lost growth on money paid in costs | $0 | $9 | $31 |
| Total costs | $57 | $187 | $341 |
| Value after costs | $10,443 | $11,390 | $12,422 |
| Impact on return, per year | 0.57% | 0.57% | 0.57% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.